These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 355033

  • 1. [A double-blind cross-over trial of a new hypolipidaemic drug (author's transl)].
    Proto C, Quadri A, Ratti S, Levi GF, Prandini BD.
    G Ital Cardiol; 1978; 8(7):743-51. PubMed ID: 355033
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [New drug combination for medical management of hyperlipemia: clinical study].
    Fischer M, Falkensammer C.
    Int J Clin Pharmacol Biopharm; 1977 Dec; 15(12):585-9. PubMed ID: 340391
    [Abstract] [Full Text] [Related]

  • 4. [Etofibrate and clofibrate in a double-blind trial on patients with raised serum-lipid levels (author's transl)].
    Kaffarnik H, Schneider J, Haase W.
    Dtsch Med Wochenschr; 1975 Nov 28; 100(48):2486-8. PubMed ID: 1104303
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Effect of a new synthetic compound (3-nicotinoyl-oxypropyl p-chlorophenoxy isobutyrate: I.612) on plasma lipids in patients with type IIa, IIb and IV hyperdyslipidemia].
    Bucalossi A, Buzzelli G, D'Alessandro A.
    Clin Ter; 1979 Apr 30; 89(2):127-49. PubMed ID: 226307
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Gemfibrozil as a lipid lowering compound in hyperlipoproteinaemia. A placebo-controlled cross-over trial.
    Vessby B, Lithell H, Boberg J, Hellsing K, Werner I.
    Proc R Soc Med; 1976 Apr 30; 69 Suppl 2(Suppl 2):32-7. PubMed ID: 798194
    [Abstract] [Full Text] [Related]

  • 10. [Multicenter clinical, double blind, and randomized study to assess the effectiveness and safety of binifibrate versus gemfibrozil in type IIa, IIb, and IV hyperlipidemia].
    Corominas Vilardell A, de Oya Otero M, Escobar Jiménez F, Anguera Vila A, Ariño Armengol B.
    An Med Interna; 1993 Nov 30; 10(11):537-41. PubMed ID: 8117868
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Therapeutic trial of a normolipemic agent: ethanolamine N-oxy-nicotinate].
    Warembourg H, Ketelers JY, Ginestet A.
    Lille Med; 1973 Dec 30; 18(10 Suppl 5):suppl 5:1331-5. PubMed ID: 4608970
    [No Abstract] [Full Text] [Related]

  • 13. [Indications and limitations of tiadenol therapy of dyslipidemia in the elderly].
    Passeri M, Cocchi C, Ceccato S, Palummeri E, Cucinotta D.
    G Clin Med; 1979 Jan 30; 60(1):49-64. PubMed ID: 456778
    [No Abstract] [Full Text] [Related]

  • 14. Gemfibrozil and clofibrate in the treatment of hyperlipidaemias. A comparative trial.
    Eisalo A, Manninen V.
    Proc R Soc Med; 1976 Jan 30; 69 Suppl 2(Suppl 2):44-6. PubMed ID: 798196
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clinical research into the hypolipemic and platelet antiaggregant activity of plafibride, Carried out in double-blind conditions and in comparison with clofibrate.
    Palmieri B, Gasparini Casari M, DiBlasio P, Zirilli E.
    Arzneimittelforschung; 1981 Jan 30; 31(10a):1863-6. PubMed ID: 7032534
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.